Rapid Micro Biosystems (RPID) Stock
Specialized contamination detection for pharmaceutical manufacturing. Here's the price, business snapshot, and what's worth knowing about Rapid Micro Biosystems in October 2026.
Rapid Micro Biosystems (RPID) develops rapid microbial detection instruments and consumables used by pharmaceutical and biotech manufacturers to monitor contamination in drug production and sterile processes. Its systems aim to speed up bioburden and sterility testing compared with traditional culture methods, which can shorten release times and improve manufacturing efficiency. The company is still relatively small (market cap around $130m) and may be unprofitable or cash‑flow negative as it invests in commercial rollout and product development. Key investor considerations include adoption by regulated customers, recurring revenue from consumables, competition from established lab suppliers, and regulatory scrutiny. As with any small medical‑technology company, shares can be volatile and subject to execution and reimbursement risks. This is general educational information and not personal advice; investors should assess suitability against their objectives, risk tolerance and time horizon, and consider seeking independent financial advice.
Rapid Micro Biosystems (RPID) Stock Forecast
Analyst price target, next 12 months
$5.90
+646.6% vs today's $0.79
Price range over the last 12 months
Close to its 12-month low
Analysts covering Rapid Micro Biosystems have a consensus 12-month target of $5.90, above the current price of $0.79.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rapid Micro Biosystems stock, with a target price of $5.9 indicating strong potential.
Financial Health
Rapid Micro Biosystems is struggling with low profits and revenue, which may affect growth opportunities.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Faster contamination detection
Systems aim to shorten bioburden and sterility testing times, which can improve manufacturing throughput — though clinical and regulatory validation is essential and outcomes can vary.
Recurring consumables model
Recurring sales of single‑use consumables can support predictable revenue as installed base grows, but revenue depends on customer adoption and usage rates.
Regulatory & adoption hurdles
Commercial success relies on uptake by regulated pharma customers and acceptance from quality teams; regulatory scrutiny and strong incumbents create execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
